Advances of HDAC dual inhibitors in breast cancer treatment
Bioorganic & Medicinal Chemistry · 2025-12 · 130 · 118372
DOI: 10.1016/j.bmc.2025.118372 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic & Medicinal Chemistry, 2025-12. Verfasst von Chuanjiang Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, PR China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Breast Neoplasms, Histone Deacetylases, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Breast cancer remains the most common prevalent malignancy among women globally, constituting the primary cause of cancer-associated mortality. While therapeutic advancements have been achieved, persistent challenges in treatment resistance, disease recurrence, and distant metastasis continue to undermine clinical outcomes. Histone deacetylases (HDACs), a conserved family of epigenetic regulators, catalyze the removal of acetyl groups from histone substrates, thereby orchestrating chromatin remodeling and transcriptional regulation. Beyond their canonical epigenetic functions, these enzymes critically modulate diverse oncogenic progresses, including cell proliferation, differentiation, and metastasis, positioning them as promising therapeutic targets in oncology. Recent studies have demonstrated the therapeutic prospects of dual-target inhibitors. Current evidence suggests such combinatorial approaches not only enhance anti-neoplastic efficacy through multi-modal mechanisms but also circumvent the drug resistance frequently observed in single-target therapy. This therapeutic paradigm shift underscores the clinical potential of HDAC-based dual inhibitors for breast cancer management. In this review, we systematically analyze recent advancements in dual-target HDAC inhibitors (HDACis), integrating mechanistic insights, preclinical evidences, and translational implications to establish a foundational framework for future therapeutic development and clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, PR China.
- Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan 250022, PR China.
- The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, PR China.
- Shandong College of Traditional Chinese Medicine, Yantai 264199, Shandong Province, PR China.
- College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, PR China. Electronic address: zhouhongleitcm@126.com.
- Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan 250022, PR China. Electronic address: jingxin1205@126.com.
Förderung
- Shandong Province Natural Science Foundation
Zitieren
APA
Wu, C., Wu, J., Ni, L., Liang, M., Feng, R., Kong, X., Zhou, H., & Nie, J. (2025). Advances of HDAC dual inhibitors in breast cancer treatment. Bioorganic & Medicinal Chemistry, 130, 118372. https://doi.org/10.1016/j.bmc.2025.118372
Vancouver
Wu C, Wu J, Ni L, Liang M, Feng R, Kong X, et al. Advances of HDAC dual inhibitors in breast cancer treatment. Bioorganic & Medicinal Chemistry. 2025;130:118372. doi:10.1016/j.bmc.2025.118372
BibTeX
@article{Wu2025,
author = {Wu, Chuanjiang and Wu, Jiyong and Ni, Linlin and Liang, Minyan and Feng, Rui and Kong, Xiaoni and Zhou, Honglei and Nie, Jing},
title = {Advances of HDAC dual inhibitors in breast cancer treatment},
journal = {Bioorganic & Medicinal Chemistry},
year = {2025},
volume = {130},
pages = {118372},
doi = {10.1016/j.bmc.2025.118372}
}
EUVIMED